Effects of HIV exposure on metabolite levels in Midfrontal Gray Matter in children: at 5 and 7 years

Study

Single voxel 1 H-MRS (SVS) data were acquired in twenty-one 5-year old (mean age \pm standard deviation = 5.5 \pm 0.4 years;15 Xhosa/6 Cape Coloured; 13 HIV-exposed, uninfected (HEU)/8 HIV-unexposed, uninfected (HUU)) and thirty-one 7-year old children (7.3 \pm 0.1 years; 24 Xhosa/7 Cape Coloured; 8 HEU/23 HUU) on a Siemens 3T Allegra Head Scanner (Siemens, Erlangen, Germany) in Cape Town, South Africa. Nine children were imaged at both ages. All HEU children were exposed to treatment for prevention of mother-to-child transmission (MTCT).

MRS data were acquired using a real-time motion and B₀ corrected [1] point resolved spectroscopy (PRESS) sequence (TR 2000 ms, TE 30 ms, 64 averages, Scan Time: 2:16 min). We collected spectra in the midfrontal gray matter (MFGM). Water reference scans were acquired in the voxel for eddy current compensation, frequency/phase correction, and to compute absolute metabolite levels. Spectra were analyzed with LCModel. R was used for all statistical analyses. A mixed effect linear regression model was used to account for repeated measures for some children.


Background

In South Africa, 95% of HIV-positive pregnant women and 68% of HIV-exposed infants have been receiving antiretroviral therapy (ART) [2,3]. Several studies [4,5,6] suggest that *in utero* ART exposure is associated with long-term neurological effects, motivating additional study of HIV-exposed uninfected (HEU) children. These studies suggest HEU children have an increased risk of neurological symptoms such as cognitive delay and motor abnormalities [5,7]. The increased risks may involve exposure to HIV antibodies, antiretroviral (ARV) drugs and environmental factors [8].

MR spectroscopy (MRS) is used for the non-invasive investigation of neuro-development in children. Many childhood neurological processes are accompanied by metabolite changes that sometimes correlate with age [9,10]. NAA is associated with neuronal density and has been shown to increase with age in childhood [9,10]. Choline remains relatively constant throughout childhood [10]. Glutamate is a neurotransmitter involved in normal cell function and neurotransmission, and is constant in childhood [10,11].

Hypothesis - From age 5 to 7 we expect to observe an increase in NAA levels as well as constant choline and glutamate levels.


Results



HEU children have HIGHER mean choline levels at age 7

Result: HEU children have HIGHER choline levels at age 7 compared to age 5 (t-test: HEU (5yrs) vs HEU (7yrs) - p = 0.005). In addition, HEU children have HIGHER choline levels at 7 years compared to HUU children (t-test at age 7: HEU vs HUU - p = 0.004). Bars represent confidence intervals.


Interpretation: Both the increased choline levels among HEU children from age 5 to 7, and the higher mean choline level at age 7 compared to HUU children, suggest a developmental difference among HEU children at age 7. Increased choline levels may imply glial proliferation/inflammation or increased cellular density.



NAA increases from age 5 to 7 in HUU children only

Result: We found an increase in NAA with age - from age 5 to age 7 (slope = 0.15; p = 0.02) across all children. The relationship is driven by HIV-unexposed children (slope = 0.23, p = 0.02). Gray represents confidence intervals.

Interpretation: The increased NAA levels may be due to increased neuronal populations and synaptic connections with age [8]. We find the increase is driven by HUU children; NAA increases with age among HUU children, however the metabolite level increase with age disappears (slope = 0.04, p = 0.6) in HEU children. The lack of age related NAA growth suggests a possible long-term effect of HIV exposure and/or ARV treatment on neuron populations, axons, dendrites and synaptic terminals.



HUU children have LOWER mean glutamate levels at age 5

Result: Glutamate levels at age 5 are LOWER in HUU compared to HEU children (p = 0.0007). Among HUU children, we found lower glutamate levels at age 5, compared to age 7 (p = 0.0004). The significant difference among HUU children in glutamate levels with age is driven by male children (p = 0.001). Bars represent confidence intervals.

Interpretation: The low mean glutamate level at age 5 among HUU children is unexpected as glutamate levels are expected to remain constant in childhood in healthy children. However, due to the small number of 5 year old children included in MRS studies of metabolite levels in childhood, age and gender related variability has not been examined in depth. This result suggests metabolite levels are influenced by both gender and age variability, suggesting that a more detailed understanding of the normal age and gender dependent variability is critical to interpreting MRS results across pediatric populations.

References

[1] Hess et al. 2011. Real-time motion and B0 corrected single voxel spectroscopy using volumetric navigators. Magnetic Resonance in Medicine 66:314-323. [2] World Health Organization, Joint United Nations Programme on HIV/AIDS, United Nations Programme on HIV/AIDS Interventions in the Health Sector. Progress report 2011. [3] Joint United Nations Programme on HIV/AIDS. 2012. Together We Will End AIDS, WHO Library Cataloguing-in-Publication Data ISBN 978-92-9173-978-3. [4] Heidari, S., L. Mofenson, M.F. Cotton, R. Marlink, Cahn P., and Katabira E. 2011. Antiretroviral drugs for preventing mother-to-child transmission of HIV: A review of potential effects on HIV-exposed but uninfected children. J Acquir Immune Defic Syndr 57:290-296. [5] Barret, B., Tardieu, M., Russtin, P., Lacroix, C., Chabyaux, M. and Blanche, S. for the French Perinatal Cohort Study Group. 2003. Register in thit of perinatal HIV infection on older school-age children in HIV-infection on older school-age children in Kinshasa and adolescents' receptive language and word recognition skills. AIDS 17:1769-1785. [6] Brackis-Cott, E., Kang, E., Dolezal, C., Abrams, E.J. independent on the neurodevelopment of prespective cohort. AIDS 17:1769-1785. [6] Brackis-Cott, E., Kang, E., Dolezal, C., Chabrams, E.J. independent on the neurodevelopment of prespective cohort. AIDS 17:1769-1785. [6] Brackis-Cott, E., Kang, E., Dolezal, C., Chabrams, E.J. independent on the neurodevelopment of prespective cohort. AIDS 17:1769-1785. [6] Brackis-Cott, E., Kang, E., Dolezal, C., Chabrams, E., Independent on the HIV-infected children in Kinshasa prespective cohort. AIDS 17:1769-1785. [7] Van, R., Stephen and Totter and Tot



SPES BONA





